Drug Topics August 21, 2024
A detailed report of study findings will be published in a peer-reviewed journal and presented at ObesityWeek 2024.
Eli Lilly and Company has announced positive topline results from its SURMOUNT-1 study evaluating the efficacy and safety of tirzepatide (Zepbound and Mounjaro) for weight management and delay in progression to type 2 diabetes (T2D) in adults with pre-diabetes and obesity or overweight.1
Most notably, tirzepatide reduced the risk of developing T2D by 94% and contributed to an average weight loss of more than 20% among participants taking the medication.
“Obesity is a chronic disease that puts nearly 900 million adults worldwide at an increased risk of other complications such as type 2 diabetes,” said Jeff Emmick, MD, PhD, senior vice...
Today's Sponsors
Today's Sponsor